Raymond James Downgrades Regeneron Pharma (REGN) to Underperform
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $797.99 +0.12%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 3
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 3
Join SI Premium – FREE
Raymond James analyst Dane Leone downgraded Regeneron Pharma (NASDAQ: REGN) from Market Perform to Underperform.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $747.33 yesterday.
You May Also Be Interested In
- Oppenheimer Downgrades Legend Biotech Corp. (LEGN) to Perform, 'CEO/Partnership/Competition Overhangs to Cap Upside'
- JPMorgan Downgrades Indorama Ventures PCL (IVL:TB) to Neutral
- JPMorgan Downgrades TRONOX (TROX) to Underweight
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
